Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.67 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.44 |
| ▸ | CBFB | Q13951 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29518706 | 0.80 | PDK2 (1.00) | PDK2PDK4LMNAKMT2AMEN1 | |
| SCHEMBL319934 | 0.80 | PDK2 (1.00) | PDK2PDK4LMNAKMT2AMEN1 | |
| SCHEMBL3624117 | 0.80 | PDK2 (0.57) | PDK2PDK4LMNAKMT2AMEN1 | |
| SCHEMBL30468523 | 0.80 | PDK2 (0.57) | PDK2PDK4LMNAKMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL27740779 | 0.78 | PDK2 (0.96) | PDK2PDK4LMNAKMT2AMEN1 | |
| SCHEMBL2313519 | 0.77 | PDK2 (0.64) | PDK2PDK4LMNAKMT2AMEN1 | |
| SCHEMBL2313521 | 0.77 | PDK2 (0.64) | PDK2PDK4LMNAKMT2AMEN1 | |
| SCHEMBL2264504 | 0.77 | PDK2 (0.64) | PDK2PDK4LMNAKMT2AMEN1 | |
| SCHEMBL2264508 | 0.77 | PDK2 (0.64) | PDK2PDK4LMNAKMT2AMEN1 | |
| SCHEMBL2266448 | 0.77 | PDK2 (0.64) | PDK2PDK4LMNAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117069647-B | Bifunctional spiro catalyst and synthetic method and application thereof | 兰州大学 | 2024-11-08 | — | — | CN | disclosed |
| CN-117069647-A | Bifunctional spiro catalyst and synthetic method and application thereof | 兰州大学 | 2023-11-17 | — | — | CN | disclosed |
| EP-2665706-B1 | NOVEL 4-AMINO-N-HYDROXY-BENZAMIDES AS HDAC INHIBITORS FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2014-10-22 | — | — | EP | disclosed |
| EP-2665706-B1 | NOVEL 4-AMINO-N-HYDROXY-BENZAMIDES AS HDAC INHIBITORS FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2014-10-22 | — | — | EP | disclosed |
| EP-2665706-A1 | NOVEL 4-AMINO-N-HYDROXY-BENZAMIDES AS HDAC INHIBITORS FOR THE TREATMENT OF CANCER | F.HOFFMANN-LA ROCHE AG (CH) | 2013-11-27 | — | — | EP | disclosed |
| CN-103328446-A | Novel 4-amino-n-hydroxy-benzamides for the treatment of cancer | HOFFMANN LA ROCHE | 2013-09-25 | — | — | CN | disclosed |
| US-8404738-B2 | 4-amino-N-hydroxy-benzamides for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404738-B2 | 4-amino-N-hydroxy-benzamides for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404738-B2 | 4-amino-N-hydroxy-benzamides for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20120190700-A1 | NOVEL 4-AMINO-N-HYDROXY-BENZAMIDES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. | 2012-07-26 | — | — | US | disclosed |
| US-20120190700-A1 | NOVEL 4-AMINO-N-HYDROXY-BENZAMIDES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. | 2012-07-26 | — | — | US | disclosed |
| WO-2012098132-A1 | NOVEL 4-AMINO-N-HYDROXY-BENZAMIDES AS HDAC INHIBITORS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012098132-A1 | NOVEL 4-AMINO-N-HYDROXY-BENZAMIDES AS HDAC INHIBITORS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| US-20120190700-A1 | NOVEL 4-AMINO-N-HYDROXY-BENZAMIDES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. | 2012-07-26 | — | — | US | disclosed |
| US-4757068-A | Lactams and bicyclic lactams useful as cholecystokinin antagonists | MERCK & CO., INC. (US) | 1988-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190700-A1 | NOVEL 4-AMINO-N-HYDROXY-BENZAMIDES FOR THE TREATMENT OF CANCER | HRH4, H1-4, HNMT | PDK2 1103/4885PDK4 618/4885LMNA 3523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.